Publications by authors named "I Lugowska"
Background: Although data on patients treated with pembrolizumab are available from clinical trials and single-country real-world reports, to our knowledge no multi-country real-world studies have investigated the use of pembrolizumab as an adjuvant treatment for stage III melanoma.
Methods: We used the European Melanoma Registry (EUMelaReg), a disease entity-based registry specific for melanoma, to examine treatment and outcomes for adult patients with stage III melanoma with lymph node involvement who had complete resection and received adjuvant treatment with pembrolizumab. The primary objectives were to describe the demographic and clinical characteristics of the included patients as well as time on adjuvant pembrolizumab treatment (TOT), real-world recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) from adjuvant pembrolizumab initiation.
Article Synopsis
- Simlukafusp alfa (FAP-IL2v) is an engineered immune cytokine aimed at enhancing immune responses specifically in tumor environments, and was evaluated with atezolizumab for treating recurrent/metastatic cervical squamous cell carcinoma (SCC) in a phase 2 study.
- A total of 48 patients with advanced cervical SCC who had previously received treatment were enrolled; the study primarily measured the objective response rate, yielding a 27% response with a median duration of 13.3 months for those who responded.
- The combination treatment showed clinical efficacy with manageable side effects, including immune cell activation, indicating a promising approach for this patient group.
Article Synopsis
- The DESTINY-PanTumor02 study investigated trastuzumab deruxtecan (T-DXd) for treating HER2-expressing solid tumors in patients who had prior treatment, focusing on IHC 3+ and 2+ tumors across seven cancer types.
- Results showed a higher objective response rate (ORR) in patients with IHC 3+ tumors (51.4%) compared to those with IHC 2+ tumors (26.5%), with median durations of response of 14.2 months and 9.8 months, respectively.
- The study concluded that T-DXd provides significant clinical benefit, especially for patients with HER2 IHC 3+ tumors, reinforcing its therapeutic potential
Article Synopsis
- * When used in combination with the PD-1 inhibitor pembrolizumab, vibostolimab has demonstrated promising antitumor activity, suggesting its potential as a therapeutic option.
- * The KEYVIBE program includes nine trials to assess the safety and efficacy of vibostolimab alone and in combination treatments for various advanced cancers, providing valuable insights for future therapies.*
The observational EURACAN prospective clinical registry dedicated to epithelioid hemangioendothelioma: The protocol of an international and collaborative effort on an ultra-rare entity.
PLoS One
August 2024
Article Synopsis
- Epithelioid hemangioendothelioma (EHE) is a rare type of cancer with unique features, but its natural history and best treatment practices are not well understood.
- The EURACAN project has created a registry to gather prospective data on newly diagnosed EHE patients to enhance understanding of the disease.
- The study will involve collecting comprehensive patient data from specialized hospitals to identify prognostic factors, treatment efficacy, and to monitor the disease's progression and outcomes over time.